ID   HEK293 CYP2C19-E92D-V5
AC   CVCL_UH05
SY   CYP2C19-E92D (no allele designation - V5 tag) Expressing HEK293 Cell Line
DR   Kerafast; EWU028
DR   Wikidata; Q94092949
RX   PubMed=28603633;
CC   Characteristics: Expresses CYP2C19 E92D with a C-terminal V5 tag.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2621; CYP2C19 (Note=With p.Glu92Asp).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Discontinued: Kerafast; EWU028; true.
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0045 ! HEK293
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 13-11-18; Last updated: 19-12-24; Version: 8
//
RX   PubMed=28603633; DOI=10.1002/prp2.314; PMCID=PMC5464343;
RA   Peterson A., Xia Z.-P., Chen G., Lazarus P.;
RT   "In vitro metabolism of exemestane by hepatic cytochrome P450s: impact
RT   of nonsynonymous polymorphisms on formation of the active metabolite
RT   17beta-dihydroexemestane.";
RL   Pharmacol. Res. Perspect. 5:e00314.1-e00314.16(2017).
//